Get the Stockscreener App
5.7774
1.72%
0.0874
Compass Therapeutics Inc stock is traded at $5.7774, with a volume of 944.02K.
It is up +1.72% in the last 24 hours and down -6.95% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$5.69
Open:
$5.53
24h Volume:
944.02K
Relative Volume:
0.45
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-16.51
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+0.13%
1M Performance:
-6.95%
6M Performance:
+68.25%
1Y Performance:
+108.94%
1-Day Range:
$5.435
$5.87
1-Week Range:
$5.32
$5.875
52-Week Range:
$1.33
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.76 | 1.01B | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.24 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Investing News Network
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Monashee Investment Management Boosts Stake in Compass Therapeutics - National Today
Signal Recap: Does Compass Therapeutics Inc have a competitive edgeQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 130% Potential Upside in Biotech - DirectorsTalk Interviews
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com - Investing.com Canada
Compass Therapeutics earnings on deck as pivotal cancer data looms - Investing.com
Compass Therapeutics Inc. expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Zacks.com Spotlights Orla Mining, FIGS, and Compass Therapeutics - Intellectia AI
Is Compass Therapeutics Inc. stock forming a cup and handleJuly 2025 Retail & Reliable Entry Point Trade Alerts - mfd.ru
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know - TipRanks
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday - MarketBeat
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Support Test: Can Compass Therapeutics Inc. sustain its profitabilityOil Prices & Weekly Return Optimization Alerts - mfd.ru
Bearish Setup: Will Compass Therapeutics Inc stock go up in YEAREarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Compass Therapeutics (NASDAQ:CMPX) Raised to "Hold" at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Research Coverage Started at Craig Hallum - Defense World
Compass Therapeutics (NASDAQ:CMPX) Raised to “Hold” at Wall Street Zen - Defense World
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
Craig-Hallum initiates coverage on Compass Therapeutics stock with Buy rating - Investing.com Canada
Compass Therapeutics stock rises after Craig-Hallum initiates coverage with Buy - Investing.com Canada
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech With 109% Potential Upside - DirectorsTalk Interviews
Will Compass Therapeutics Inc. outperform during market ralliesJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Compass Therapeutics (NASDAQ:CMPX) Cut to "Sell" at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen - Defense World
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Evaluating the 112.66% Potential Upside - DirectorsTalk Interviews
Canaccord Genuity raises Compass Therapeutics stock price target on Phase 2/3 data expectations - Investing.com Canada
Compass Therapeutics (NASDAQ:CMPX) Sets New 1-Year HighHere's What Happened - MarketBeat
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com - Investing.com Nigeria
Compass Therapeutics stock hits 52-week high at 6.51 USD - Investing.com
Wall Street Zen Upgrades Compass Therapeutics (NASDAQ:CMPX) to "Hold" - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year HighHere's Why - MarketBeat
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High? - Finviz
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Institution Moves: Is Compass Therapeutics Inc stock a top performer YTD2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):